Feb 18, 2022 / 12:00PM GMT
Holly Manning - Agios Pharmaceuticals, Inc. - Senior Director of IR
All right. It's 7:00, so let's go ahead and get started. Thank you, everyone, for joining our approval event today. We will -- we have some prepared remarks. We'll go through our label and commercial plans. And then at the end, we'll have time for Q&A. (Operator Instructions) So Jackie, I will turn it over to you.
Jacqualyn A. Fouse - Agios Pharmaceuticals, Inc. - CEO & Director
Thank you, Holly. Good early morning, everyone, and thank you for joining us early this morning. It's a very exciting time for us at Agios today as we got our first genetically defined disease indication drug approval yesterday, and we're just thrilled with that and look forward to speaking with you about it today.
Just as a reminder, less exciting, but necessary, this presentation will include forward-looking statements. Before we get started with the specifics of today's -- or yesterday, actually, announcement I want to start with one of the key ways that we differentiate ourselves at Agios with what
Agios Pharmaceuticals Inc to Discuss the FDA Approval of PYRUKYND Call Transcript
Feb 18, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers